---
schema_version: "secwatch.filing_event.v1"
accession: "0001746473-25-000173"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:51:42.793080+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics Q3 net loss narrows to $26.3M; BEACON-IPF close out near completion

## Summary
- Net loss $26.3M vs $57.8M YoY; R&D expense fell to $17.9M from $47.8M.
- Cash, equivalents and short-term investments $243.3M as of Sept 30, 2025.
- Phase 1 trial of PLN-101095 completed enrollment; data expected Q4 2025.
- BEACON-IPF close out activities to be completed in Q4 2025.
- Voluntary prepayment of Oxford Finance LLC loan completed in October 2025.

## SEC filing metadata
- accession: 0001746473-25-000173
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000174647325000173/0001746473-25-000173-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000174647325000173/plrx-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001746473-25-000173
- JSON: https://secwatch.observer/filing/0001746473-25-000173.json
- Plain text: https://secwatch.observer/filing/0001746473-25-000173.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.